Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Macrogenics (MGNX)

Macrogenics (MGNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
FDA Removes Partial Clinical Hold on MacroGenics’ LINNET Study GlobeNewswire - Wed Apr 8, 3:30PM CDT

• Plan to resume enrollment in clinical study of lorigerlimab in gynecologic cancers   • On track to provide mid-2026 program update  ROCKVILLE, MD, April 08, 2026 (GLOBE NEWSWIRE) -- MacroGenics,...

MGNX : 3.01 (-1.31%)
MacroGenics: Q4 Earnings Snapshot AP - Mon Mar 9, 3:23PM CDT

MacroGenics: Q4 Earnings Snapshot

MGNX : 3.01 (-1.31%)
MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures GlobeNewswire - Mon Mar 9, 3:01PM CDT

Initial MGC026 (B7-H3 ADC) Phase 1 results in mid-2026 Initial MGC028 (ADAM9 ADC) Phase 1 results in second half of 2026 Lorigerlimab Phase 2 LINNET study update in mid-2026 IND submission for...

MGNX : 3.01 (-1.31%)
MacroGenics to Participate in Upcoming Investor Conferences GlobeNewswire - Thu Feb 26, 4:30PM CST

ROCKVILLE, MD, Feb. 26, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer,...

MGNX : 3.01 (-1.31%)
MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial GlobeNewswire - Mon Feb 23, 5:14PM CST

ROCKVILLE, MD, Feb. 23, 2026 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment...

MGNX : 3.01 (-1.31%)
MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference GlobeNewswire - Tue Nov 25, 2025

ROCKVILLE, MD, Nov. 25, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer,...

MGNX : 3.01 (-1.31%)
MacroGenics: Q3 Earnings Snapshot AP - Wed Nov 12, 2025

MacroGenics: Q3 Earnings Snapshot

MGNX : 3.01 (-1.31%)
MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress GlobeNewswire - Wed Nov 12, 2025

Achieved additional $75 million in partnering proceeds from Sanofi and Gilead Granted license to additional preclinical program to Gilead that leverages MacroGenics’ novel T-cell engager platform...

MGNX : 3.01 (-1.31%)
MacroGenics to Participate in the Stifel 2025 Healthcare Conference GlobeNewswire - Thu Nov 6, 2025

ROCKVILLE, MD, Nov. 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer,...

MGNX : 3.01 (-1.31%)
MacroGenics to Present at H.C. Wainwright 27th Annual Global Investment Conference GlobeNewswire - Tue Sep 2, 2025

ROCKVILLE, MD, Sept. 02, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer,...

MGNX : 3.01 (-1.31%)

Barchart Exclusives

Warren Buffett’s Berkshire Hathaway Is Losing Money in This Dividend Stock: Can It Work for You? Barchart - Tue Apr 28, 6:30PM CDT
Domino's Pizza has a dividend yield of 2.4%, and its dividends have risen at an annualized pace of nearly 20% over the last 10 years. Does that make the stock a buy? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.